简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

Genfit S.A. GAAP每股收益-0.20欧元，收入3567万欧元

2025-09-23 12:52

  • Genfit S.A. press release (OTCPK:GNFTF): 1H GAAP EPS of -€0.20.
  • Revenue of €35.67M (-41.7% Y/Y).
  • Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries.
  • "We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its pipeline focused on Acute-on-Chronic Liver Failure and support general corporate purposes. "

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2025 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号